MITCHELL KEEGAN, VP DEVELOPMENT - Verastem
MITCHELL KEEGAN, VP DEVELOPMENT 1 Novel Drugs Targeting Cancer Stem Cells. Page PI3K/mTOR dual inhibitor GDC‐0980 showed 4 PRs among 33 mesothelioma patients in a phase 1 study ECCO 2013 4 Compound Company ... Read Here
METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND ...
Include but are not limited to, GSK 2126458, GDC-0980, GDC-0941, Sanofi XL147, XL756, XL147, PF-46915032, Novartis BEZ 235, BKM 120, CAL-101, CAL 263, SF1126 and PX-886. In one Typically the polymorphic site is occupied by a base other than the reference base. For ... Read Article
Malignant Pleural Mesothelioma: State Of The Art And Projects
Malignant Pleural Mesothelioma: State of the art and projects Rolf Stahel, MD University Hospital Zurich, Phase I study with GDC-0980, a inhibitor of class I PI3K and mTOR kinase: Malignant Pleural Mesothelioma. Title Dr_Stahel_Mesothelioma Barcelona 18-11-201 Author: ... View Document
Impact Case Study (REF3b) Institution: The Institute Of ...
GDC-0980, has also been evaluated in patients by ICR Faculty member Professor de Bono with this drug demonstrating antitumour activity against mesothelioma. The importance of the ICR’s drug discovery research work is evidenced by its receipt of the AACR . Impact case study (REF3b) ... Visit Document
Review - Oxford Journals
Mesothelioma is a fatal disease predominantly arising in the pleural cavity and less so in the peritoneal cavity. Altered NF2 signaling NCT00854152 GDC-0980 PI3K/mTOR inhibitor I PK, MTD August 2014 NCT01655225 LY3023414 PI3K/mTOR inhibitor I Recommended phase II ... Fetch Content
Provisional Programme 15.09
Models of Mesothelioma 15.3 D Baratti Malignant Peritoneal Mesothelioma: Incorporation of Novel Pathological Grading into a Recently Proposed TNM Classification Improves Outcome Prediction 16.3 J Friedberg The State of the Art Technique for Lung- Sparing ... Access This Document
Developments In Targeted Therapies
GDC-0980, an oral PI3K/mTOR inhibitor, administered to patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL) 2 cPRs in mesothelioma pts 8 mg PI3K R88Q mutation 50mg SD on study 6 pts > 6 months 3 pts > 18 months ... Fetch Content
Giovanni Luca Ceresoli Thoracic & GU Oncology Unit Humanitas ...
MESOTHELIOMA Giovanni Luca Ceresoli Thoracic & GU Oncology Unit Humanitas Gavazzeni, Bergamo GDC 0980, 30 mg orally daily Phase I I MPM + MPM expanded cohort at P2RD Overall 33 pts; 4 PR, RR 12% PI3K mut ti ns nd pTEN lssunc mm n ... View Doc
Mitchell Keegan, Ph.D. - Verastem
ORAL40.05: VS-6063 & VS-5584 Exhibit Synergistic Anticancer Activity in Pre-clinical Models of Mesothelioma – Mitchell Keegan, P h.D. THE CANCER STEM CELL INHIBITORS VS-6063 AND • PI3K/mTOR dual inhibitor GDC‐0980 showed 4 ... Get Document
MET And PI3K/mTOR As A Potential Combinatorial Therapeutic ...
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma Rajani Kanteti1, Immanuel Dhanasingh1, Ichiro Kawada1, Frances E. Lennon1, Qudsia Arif2, ... Visit Document
IMig2014 Cape Town Final Scientific Programme 21-24 October ...
IMig2014 Cape Town Final Scientific Programme Mesothelioma--From Chaos to Mitochondrial Functionality: The Dual PI3K/mTOR Inhibitor GDC-0980 Bypasses Multicellular Resistance of Mesothelioma Spheroids 22.5 A Clive 1130 ... Get Content Here
Genentech
Development, production, and marketing of human therapeutics. Includes research history, product pipeline, global corporate and career information. San Francisco, California. ... Read Article
PI3K/MTOR KINASE INHIBITOR VS-5584 - ECMC Network
Rationale • Strong pre-clinical data demonstrating synergy of VS-5584 and VS-6063 in pre-clinical mesothelioma models • 3 FAKi’s have demonstrated SD in meso patients with relapsed disease • PI3k/mTOR inhibitor GDC-0980 demonstrated ORR in meso patients with relapsed disease ... Get Document
PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer. Department of Cancer Biology, Abramson Family Cancer Research Institute, University of mesothelioma (MM) cells and inhibits TOR signaling without activating Akt or ERK. Marjorie ... Read Here
Patent WO2014115859A2 - Combination Molecularly Targeted Drug ...
YouTube; News; Gmail; Drive; More. Calendar; Translate; prostate cancer, bladder cancer, colon cancer, colon cancer, rectal cancer, skin cancer, mesothelioma, lymphoma and SAR245408 / XL147, SAR245409 / XL765, BGT226, GS-1101 / CAL-101, GDC-0980 / RG7422, PX-866, GSK2126458, PF-4691502 ... View Video
Patent WO2012164060A1 - Methods Of Treating mesothelioma With ...
4. A method for the treatment of mesothelioma comprising administering to patient with mesothelioma a therapeutically effective amount of GDC-0980 having the structure ... View Video
And Risk Assessment - Clinical Cancer Research
And Risk Assessment Marc Ladanyi1*, Marjorie G. Zauderer2, Lee M. Krug2, and GDC 0980, have shown promise in MPM. BEZ 235, malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001; 357:444-5. 36. ... Document Retrieval
PLOS ONE: Autophagy Correlates With The Therapeutic ...
Abstract. Malignant pleural mesothelioma is a highly chemoresistant solid tumor. We have studied this apoptotic resistance using in vitro and ex vivo three-dimensional models, whi ... Read Article
Richard H. Scheller |Headof GRED Genentech Research & Early ...
Mesothelioma; diagnosed in 2007; Received 8 mg daily GDC-0980 (RG7422) Unconfirmed partial response after Cycle1 Overall decrease in target lesions ~32% Pretreatment End of Cycle1 Wagner et al, AACR 2009. 23 Diagnostic assay development for PI3K programs 1. ... Access Document
Malignant Pleural Mesothelioma
Mesothelioma Questions 2 The following statement about multimodality therapy of pleural mesothelioma is correct 1) The preferred chemotherapy consists of carboplatin ... Get Content Here
Searching For Targets For The Systemic Therapy Of mesothelioma
2 . Abstract . Malignant mesothelioma is an incurable disease associated with asbestos exposure arising in the pleural cavity and less frequently in the peritoneal cavity. ... Access Content
Pushing The Envelope In The MTOR Pathway. The Second ...
Second generation inhibitors are displayed in the second and subsequent rows. Structures of NVP-BGT226, GDC-0980, SB-2312, INK (FRB) domain adjacent to the catalytic site of the mTOR protein . Several studies have shown that renal cell carcinoma, mesothelioma, and appendiceal ... View Video
• Wikipedia • Multi Media; Hide Article Tools. Abstract. Print this article. GDC-0980 is showing promising clinical activity in phase II trials.68 At the time of writing, one clinical trial with more than 100 patients has almost been completed with activity seen in mesothelioma, ... Read Article
Final Pr.No.
Final Pr.No. MO09.01 Title Evaluation of tolerability and anti-tumor activity of GDC-0980, an oral PI3K/mTOR inhibitor, administered to patients with advanced malignant pleural mesothelioma (MPM) ... Access Document
No comments:
Post a Comment